Max-10181 / Maxinovel - LARVOL DELTA

Characterization of Clinically Evaluated Small-Molecule Inhibitors of PD-L1 for Immunotherapy. (PubMed, ACS Med Chem Lett) - "In this study, we characterized three small-molecule PD-L1 inhibitors, Evixapodlin, MAX-10181, and INCB086550, currently undergoing clinical trials for cancers such as non-small cell lung cancer, renal cell carcinoma, urothelial carcinoma, hepatocellular carcinoma, and melanoma...Cellular assays revealed dose-dependent T-cell activation, demonstrating the immunomodulatory potential of each compound and its cytotoxicity profiles. These findings underscore the promise of small-molecule PD-L1 inhibitors as viable alternatives to antibody-based therapies in cancer immunotherapy."

Journal • Genito-urinary Cancer • Hepatocellular Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer

Orally active PD-L1 inhibitor MAX-10181 in combination with temozolomide effectively prolonged survival in GBM animal model study (AACR 2024) - "In this study, the combination of MAX-10181 with TMZ effectively prolonged the survival by 50% in comparison with TMZ single therapy. Details of this study will be reported in this meeting."

Combination therapy • Preclinical • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor

Combination of a PD-1/CTLA-4 bispecific antibody with orally active PD-L1 inhibitor MAX-10181 effectively increased the percentage of tumors inhibited in animal model study (AACR 2023) - "The key observations are as follow:•The PD-1/CTLA-4 bispecific antibody group (n=10, average starting tumor volume= 68 mm3) demonstrated (a) 2 tumors (20%) in the slow volume shrinking mode with volume between 60-20 mm3, and (b) 4 tumors (40%) in the fast volume growing mode with volume above 500 mm3 •The combination group (n=10, average starting tumor volume= 68 mm3) demonstrated (a) 2 tumors (20%) in the fast volume shrinking mode with volume less than 20 mm3, (b) 1 tumor (10%) in the slow volume shrinking mode with volume between 60-20 mm3, and (c) only 1 tumor (10%) in the fast volume growing mode with volume above 500 mm3These results indicate the potential of prolonged OS/PFS to combine PD-1/CTLA-4 bispecific antibody with orally active, small molecule MAX-10181 which recently completed Phase I trial. We will present the full study results in the coming AACR meeting."

Late-breaking abstract • Preclinical • Oncology • CTLA4 • PD-1

MAX-10181 Given Orally to Patients With Advanced Solid Tumor (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: Maxinovel Pty., Ltd.; Trial completion date: Nov 2021 ➔ Nov 2022; Trial primary completion date: Oct 2021 ➔ Oct 2022

Clinical • Trial completion date • Trial primary completion date • Oncology • Solid Tumor • MRI

PD-L1: MAX-10181 in Patients With Advanced Solid Tumor (clinicaltrials.gov) - P1; N=80; Recruiting; Sponsor: Maxinovel Pty., Ltd.

Clinical • New P1 trial • Oncology • Solid Tumor • MRI

MAX-10181 Given Orally to Patients With Advanced Solid Tumor (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: Maxinovel Pty., Ltd.; Trial completion date: Jun 2021 ➔ Nov 2021; Trial primary completion date: Dec 2020 ➔ Oct 2021

Clinical • Trial completion date • Trial primary completion date • Oncology • Solid Tumor